Gherardo Mazziotti

Prof. Gherardo Mazziotti

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2007 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
ECE. Canalis
E. Canalis
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
AGA. Giustina
A. Giustina
JBJ. P. Bilezikian
J. P. Bilezikian

1 August 2008 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
AGAndrea Giustina
Andrea Giustina
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
ECErnesto Canalis
Ernesto Canalis
GH and IGF-I are important regulators of bone homeostasis and are central to the achievement of normal longitudinal bone growth and bone mass. Although GH may act directly on skeletal cells, most of its effects are mediated by IGF-I, which is present in the systemic circulation and is synthesized by peripheral tissues. The availability of IGF-I is regulated by IGF binding proteins. IGF-I enhances the differentiated function of the osteoblast and bone formation. Adult GH deficiency causes low bone turnover osteoporosis with high risk of vertebral and nonvertebral fractures, and the low bone mass can be partially reversed by GH replacement. Acromegaly is characterized by high bone turnover, which can lead to bone loss and vertebral fractures, particularly in patients with coexistent hypogonadism. GH and IGF-I secretion are decreased in aging individuals, and abnormalities in the GH/IGF-I axis play a role in the pathogenesis of the osteoporosis of anorexia nervosa and after glucocorticoid exposure.

1 October 2020 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ALAndrea Lania
Andrea Lania
MSMaria Teresa Sandri
Maria Teresa Sandri
MCMiriam Cellini
Miriam Cellini
MMMarco Mirani
Marco Mirani
ELElisabetta Lavezzi
Elisabetta Lavezzi
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
Objective:: This study assessed thyroid function in patients affected by the coronavirus disease-19 (COVID-19), based on the hypothesis that the cytokine storm associated with COVID-19 may influence thyroid function and/or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly act on thyroid cells, such as previously demonstrated for SARS-CoV-1 infection. Design and methods:: This single-center study was retrospective and consisted in evaluating thyroid function tests and serum interleukin-6 (IL-6) values in 287 consecutive patients (193 males, median age: 66 years, range: 27–92) hospitalized for COVID-19 in non-intensive care units. Results:: Fifty-eight patients (20.2%) were found with thyrotoxicosis (overt in 31 cases), 15 (5.2%) with hypothyroidism (overt in only 2 cases), and 214 (74.6%) with normal thyroid function. Serum thyrotropin (TSH) values were inversely correlated with age of patients (rho −0.27; P < 0.001) and IL-6 (rho −0.41; P < 0.001). In the multivariate analysis, thyrotoxicosis resulted to be significantly associated with higher IL-6 (odds ratio: 3.25, 95% confidence interval: 1.97–5.36; P < 0.001), whereas the association with age of patients was lost (P = 0.09). Conclusions:: This study provides first evidence that COVID-19 may be associated with high risk of thyrotoxicosis in relationship with systemic immune activation induced by the SARS-CoV-2 infection.

1 May 2006 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
AAAlberto Angeli
Alberto Angeli
JBJohn P. Bilezikian
John P. Bilezikian
ECErnesto Canalis
Ernesto Canalis
AGAndrea Giustina
Andrea Giustina

1 October 2010 in The American Journal of Medicine
Verified
Journal Article
Closed access
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
ECErnesto Canalis
Ernesto Canalis
AGAndrea Giustina
Andrea Giustina

20 December 2013 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
PKPeter Kamenický
Peter Kamenický
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
MLMarc Lombès
Marc Lombès
AGAndrea Giustina
Andrea Giustina
PCPhilippe Chanson
Philippe Chanson
Besides their growth-promoting properties, GH and IGF-1 regulate a broad spectrum of biological functions in several organs, including the kidney. This review focuses on the renal actions of GH and IGF-1, taking into account major advances in renal physiology and hormone biology made over the last 20 years, allowing us to move our understanding of GH/IGF-1 regulation of renal functions from a cellular to a molecular level. The main purpose of this review was to analyze how GH and IGF-1 regulate renal development, glomerular functions, and tubular handling of sodium, calcium, phosphate, and glucose. Whenever possible, the relative contributions, the nephronic topology, and the underlying molecular mechanisms of GH and IGF-1 actions were addressed. Beyond the physiological aspects of GH/IGF-1 action on the kidney, the review describes the impact of GH excess and deficiency on renal architecture and functions. It reports in particular new insights into the pathophysiological mechanism of body fluid retention and of changes in phospho-calcium metabolism in acromegaly as well as of the reciprocal changes in sodium, calcium, and phosphate homeostasis observed in GH deficiency. The second aim of this review was to analyze how the GH/IGF-1 axis contributes to major renal diseases such as diabetic nephropathy, renal failure, renal carcinoma, and polycystic renal disease. It summarizes the consequences of chronic renal failure and glucocorticoid therapy after renal transplantation on GH secretion and action and questions the interest of GH therapy in these conditions.